Overview
Candel Therapeutics is a newly public clinical-stage biotechnology company pioneering the development of viral based immunotherapies for the treatment of solid tumors. Candel’s products are designed to significantly help patients fight their cancer while maintaining quality of life – from early – to late-stage disease. We care about our team, our patients, and our community. We have a robust pipeline with clinical assets in phase 1, 2 and 3 for the treatment of prostate, brain, lung and pancreatic cancers Please visit www.Candeltx.com for additional information.